What Has Been the Progress and Growth of the Chemotherapy Induced Nausea and Vomiting CINV Market in Recent Years?
The chemotherapy induced nausea and vomiting cinv market has seen considerable growth due to a variety of factors.
• The market for chemotherapy-induced nausea and vomiting (CINV) has seen robust growth in the past few years. With a projected compound annual growth rate (CAGR) of 7.9%, it is expected to rise from $2.92 billion in 2024 to $3.15 billion in 2025.
The market's growth during the historical period can be attributed to factors such as an increase in the use of chemotherapy, the development of better antiemetic drugs, clinical guidelines, and patient advocacy.
What Is The Expected Growth In The Chemotherapy Induced Nausea and Vomiting CINV Market Size Evolve over the Forecast Period?
The chemotherapy induced nausea and vomiting cinv market is expected to maintain its strong growth trajectory in upcoming years.
• The market for chemotherapy-induced nausea and vomiting (CINV) is projected to experience significant expansion in the coming years, reaching a value of $4.2 billion by 2029 with a compound annual growth rate (CAGR) of 7.5%.
The expected increase during the prediction period can be linked to personalized medicine, advances in antiemetic agents, the adoption of telehealth and remote monitoring, as well as health equity initiatives. Combination antiemetic treatments, supportive care services, digital health tools, and survivorship care form the key trends anticipated in the future.
What Main Forces Are Fueling Expansion In The Chemotherapy Induced Nausea and Vomiting CINV Market?
Rising cancer rates are projected to fuel the expansion of the chemotherapy-induced nausea and vomiting (CINV) market. The uncontrolled and widespread growth of some body cells characterizes cancer. The continuous rise in cancer cases necessitates the creation of more potent and adapted anti-emetic treatments to mitigate CINV, a harrowing chemotherapy side effect. This increased focus on CINV management has led to progress in comprehending its underlying causes and producing new treatments. For example, predictions made by the American Cancer Society (ACS), a US-based voluntary health group dedicated to eliminating cancer, anticipate approximately 1.9 million new cancer case (about 5370 cases each day) and 609,820 cancer deaths (around 1,670 deaths each day) in the US in January 2023. As a result, the growing prevalence of cancer is expected to stimulate the chemotherapy-induced nausea and vomiting (CINV) market. Moreover, increasing favorable regulatory measures are projected to drive the chemotherapy-induced nausea and vomiting (CINV) market's progress. Regulatory initiatives, taken by regulatory authorities to establish, implement, or enforce regulations, can be leveraged to foster the prevention and control of chemotherapy-induced nausea and vomiting (CINV) and also to establish and enforce guidelines for CINV prevention and control. For instance, in 2023, as per the Food and Drug Administration, a federal agency dedicated to protecting public health in the US, the Center for Drug Evaluation and Research (CDER) approved 55 new drugs for chemotherapy-induced nausea and vomiting (CINV) in October 2024. Therefore, these increasingly favorable regulatory measures are serving to further the growth of the chemotherapy-induced nausea and vomiting (CINV) market.
What Are The Primary Segments In The Global Chemotherapy Induced Nausea and Vomiting CINV Market?
The chemotherapy-induced nausea and vomiting (CINV) market covered in this report is segmented –
1) By Form: Injectables, Oral, Transdermal Patches
2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Class
3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)
4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores
5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications
Subsegments:
1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections
2) By Oral: Tablets, Capsules, Liquid Formulations
3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches
Pre-Book The Chemotherapy Induced Nausea and Vomiting CINV Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Chemotherapy Induced Nausea and Vomiting CINV Market?
Leading businesses in the chemotherapy-induced nausea and vomiting (CINV) marketplace are focusing on fresh product advancements, like fixed intravenous antiemetic, to establish a competitive edge. A fixed intravenous antiemetic is a pre-set quantity of medication given via an IV to prevent or manage nausea and vomiting, which is typically utilized in chemotherapy or following surgical procedures. To illustrate, Glenmark Pharmaceuticals Limited, a pharmaceutical, generics, and over-the-counter (OTC) products manufacturer from India, launched AKYNZEO I.V. in India in January 2023. This was the inaugural fixed intravenous antiemetic combination created to curb chemotherapy-induced nausea and vomiting (CINV). This product fuses netupitant and palonosetron, aiming to alleviate both the immediate and subsequent stages of nausea and vomiting. It provides the convenience of a single dosage, enhances complete response rates, and improves the quality of life for cancer patients. Clinical trials indicate it is particularly effective for patients undergoing highly emetogenic chemotherapy.
Who Are the Key Players In The Chemotherapy Induced Nausea and Vomiting CINV Market?
Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are:
• Pfizer Inc.
• Roche Holding AG
• Merck & Co. Inc.
• AbbVie Inc.
• Novartis AG
• AstraZeneca PLC
• GlaxoSmithKline PLC
• Baxter International Inc.
• Teva Pharmaceuticals Industries Ltd.
• Bausch Health Companies Inc.
• Eisai Co. Ltd.
• Jazz Pharmaceuticals PLC
• Ono Pharmaceutical Co. Ltd.
• Dr. Reddy’s Laboratories Ltd.
• Kyowa Kirin Inc.
• Amneal Pharmaceuticals Inc.
• Mundipharma International Limited
• Insys Therapeutics Inc.
• Lupin Limited
• Helsinn Holding S.A.
• Heron Therapeutics Inc.
• Camurus AB
• Cadila Pharmaceuticals Limited
• Acacia Pharma Ltd.
• Soligenix Inc.
What Is The Most Dominant Region In The Chemotherapy Induced Nausea and Vomiting CINV Market?
North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
